Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5CNS 3Breast 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1

Conditions

Sarcoma 108Central Nervous System Neoplasms 42Osteosarcoma 38Gliosarcoma 34Glioblastoma 34Rhabdomyosarcoma 27Lymphoma 22Fibrosarcoma 22Liposarcoma 21Leiomyosarcoma 20Neuroblastoma 19Hemangiosarcoma 19Astrocytoma 19Sarcoma, Synovial 18Neuroectodermal Tumors, Primitive, Peripheral 18Dendritic Cell Sarcoma, Interdigitating 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neurofibrosarcoma 17Histiocytoma, Malignant Fibrous 17Brain Neoplasms 17Sarcoma, Kaposi 16Malignant mesenchymal tumor 16Burkitt Lymphoma 16Ovarian Neoplasms 15Recurrence 14Leukemia 14Sarcoma, Alveolar Soft Part 12Oligodendroglioma 12AIDS-related Kaposi sarcoma 12Hemangiopericytoma, Malignant 11

Interventions

Paclitaxel 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neurotoxicity Syndromes × Sarcoma × Clear all
NCT00003624 2013-04-11

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

GOG Foundation

Phase 2 Terminated
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡